JUN 14, 2017 4:13 PM PDT

Identifying A Rare Autoimmune Disease at the Cellular Level

WRITTEN BY: Kara Marker

Diagnostic tests for a rare autoimmune disease called anti-phospholipid antibody syndrome (APS) are unreliable, and treatments are not sustainable long-term. However, a new discovery of the disease’s causation from the University of Geneva might alter solutions for both of these problems.

 Anti-phospholipid antibody syndrome occurs when the immune system attacks normal proteins in the blood.

APS is characterized by autoantibodies in the blood plasma that target anticoagulant proteins, leading to excessive blood clotting. Binding of these autoantibodies can occur in the blood vessels and in the placenta, with dangerous consequences such as venous thromboses, strokes, and miscarriages. APS is rare, affecting less than one percent of the population, but this condition often occurs simultaneously with lupus or rheumatoid arthritis.

Current diagnostic approaches for APS require the expertise of a hematologist, an extensive review of a patient’s medical history, and blood tests scanning for three antibodies that indicate APS: anticardiolipin, beta-2 glycoprotein I, lupus anticoagulant. However, variability, specificity, and sensitivity of these tests are not always dependable.

Treatment options for APS almost exclusively involve oral anticoagulants, but extended use raises risk of adverse side effects, especially for pregnant women.

"The current diagnostic tests use the entire protein, which reduces its specificity and leads to standardization issues,” explained Karim Brandt, a researcher from the study. “Consequently, two tests are required at an interval of 12 weeks after a thrombotic episode or following one or more miscarriages. Our new test specifically targets this pathogenic antibody, with rapid and more accurate results."

The new diagnostic approach is to be devised based upon the discovery of the precise location of anti-phospholipid antibody binding. Identifying the exact location of binding allowed scientists to study in detail how the binding occurs and its specific effects on blood clotting. They found that binding triggers the release of pro-inflammatory and pro-thrombotic factors that are the basis of the condition’s dangerous consequences. 

"Our breakthrough could also give rise to a targeted treatment that would neutralize specific pathogenic antibodies, reducing not just their actions but also the side effects associated with the current treatment,” Brandt explained. “It would involve injecting the protein motif we have identified into a patient's circulatory system so that it explicitly binds itself to the pathogenic antibody and prevents it from causing harm."

The present study was published in the journal Haematologica.

Sources: National Heart, Lung, and Blood Institute, University of Geneva

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 22, 2019
Immunology
JUL 22, 2019
How to Kill Superbugs
https://www.technologynetworks.com/immunology/news/enhancing-the-infection-fighting-potential-of-natural-products-321553...
SEP 27, 2019
Immunology
SEP 27, 2019
Diseases We Share with Our Canine Companions: Autoimmune Encephalitis in Dogs
Like humans, dogs can develop autoimmune encephalitis, and it’s common - mostly affecting smaller breeds and young adult dogs. Now scientists underst...
SEP 29, 2019
Drug Discovery & Development
SEP 29, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
DEC 05, 2019
Drug Discovery & Development
DEC 05, 2019
New Injection that Treats Peanut Allergy
Peanut allergies affect between 1 and 3% of the US population. Associated with a heightened risk of severe anaphylactic reactions, oral immunotherapy is th...
FEB 04, 2020
Immunology
FEB 04, 2020
The Gut Deploys Protective Mechanisms in Coordination with Your Mealtime Habits
At mealtime, every mouthful of food contains a possible risk of incoming pathogens to the digestive system. The gut takes protective measures to account fo...
Loading Comments...